[go: up one dir, main page]

RU2017133854A - VECTOR - Google Patents

VECTOR Download PDF

Info

Publication number
RU2017133854A
RU2017133854A RU2017133854A RU2017133854A RU2017133854A RU 2017133854 A RU2017133854 A RU 2017133854A RU 2017133854 A RU2017133854 A RU 2017133854A RU 2017133854 A RU2017133854 A RU 2017133854A RU 2017133854 A RU2017133854 A RU 2017133854A
Authority
RU
Russia
Prior art keywords
cell
viral vector
mitogenic
transmembrane protein
retroviral
Prior art date
Application number
RU2017133854A
Other languages
Russian (ru)
Other versions
RU2017133854A3 (en
Inventor
Мартен ПЮЛЕ
Лейла МЕККАУИ
Original Assignee
ЮСиЭл БИЗНЕС ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52876362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2017133854(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ЮСиЭл БИЗНЕС ПиЭлСи filed Critical ЮСиЭл БИЗНЕС ПиЭлСи
Publication of RU2017133854A publication Critical patent/RU2017133854A/en
Publication of RU2017133854A3 publication Critical patent/RU2017133854A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/852—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from cytokines; from lymphokines; from interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (53)

1. Ретровирусный или лентивирусный вектор, имеющий вирусную оболочку, содержащую:1. Retroviral or lentiviral vector having a viral envelope containing: (i) митогенный, активирующий T-клетки трансмембранный белок, содержащий митогенный домен и трансмембранный домен; и/или(i) a mitogenic T cell activating transmembrane protein comprising a mitogenic domain and a transmembrane domain; and / or (ii) активирующий T-клетки трансмембранный белок на основе цитокинов, содержащий цитокиновый домен и трансмембранный домен,(ii) a T cell activating cytokine-based transmembrane protein comprising a cytokine domain and a transmembrane domain, где митогенный, активирующий T-клетки трансмембранный белок или активирующий T-клетки трансмембранный белок на основе цитокинов не являются частью гликопротеина вирусной оболочки.where the mitogenic T cell activating transmembrane protein or T cell activating cytokine-based transmembrane protein are not part of the viral envelope glycoprotein. 2. Вирусный вектор по п.1, содержащий митогенный, активирующий T-клетки трансмембранный белок, связывающийся с CD3, CD28, CD134 или CD137.2. The viral vector according to claim 1, containing a mitogenic, T-cell activating transmembrane protein that binds to CD3, CD28, CD134 or CD137. 3. Вирусный вектор по п.2, где митогенный, активирующий T-клетки трансмембранный белок содержит связывающий домен из OKT3, 15E8, TGN1412, OX40L или 41BBL.3. The viral vector according to claim 2, where the mitogenic, T-cell activating transmembrane protein contains a binding domain of OKT3, 15E8, TGN1412, OX40L or 41BBL. 4. Вирусный вектор по п.1, содержащий два или более митогенных, активирующих T-клетки трансмембранных белка в вирусной оболочке.4. The viral vector according to claim 1, containing two or more mitogenic, T-cell activating transmembrane proteins in the viral envelope. 5. Вирусный вектор по п.4, содержащий первый митогенный, активирующий T-клетки трансмембранный белок, связывающийся с CD3, и второй митогенный, активирующий T-клетки трансмембранный белок, связывающийся с CD28.5. The viral vector according to claim 4, comprising a first mitogenic T cell activating transmembrane protein that binds to CD3 and a second mitogen T cell activating transmembrane protein that binds to CD28. 6. Вирусный вектор по п.1, содержащий активирующий T-клетки трансмембранный белок на основе цитокинов, содержащий цитокин, выбранный из ИЛ-2, ИЛ-7 и ИЛ-15.6. The viral vector according to claim 1, containing a T-cell activating cytokine-based transmembrane protein containing a cytokine selected from IL-2, IL-7 and IL-15. 7. Вирусный вектор по п.1, содержащий гетерологичный гликопротеин вирусной оболочки, из которого получают псевдотипированный вирусный вектор.7. The viral vector according to claim 1, containing a heterologous viral envelope glycoprotein from which a pseudotyped viral vector is derived. 8. Вирусный вектор по п.7, где гликопротеин оболочки получают из RD114 или одного из его вариантов, VSV-G, вируса лейкоза гиббона (GALV), или он является гликопротеином оболочки амфотропного вируса, оболочки вируса кори или оболочки ретровируса бабуина.8. The viral vector of claim 7, wherein the sheath glycoprotein is derived from RD114 or one of its variants, VSV-G, Gibbon leukemia virus (GALV), or it is a glycoprotein of the amphotropic virus sheath, measles virus sheath or baboon retrovirus sheath. 9. Вирусный вектор по п.1, где вирусная оболочка также содержит:9. The viral vector according to claim 1, where the viral envelope also contains: (iii) белок-метку, содержащую:(iii) a tag protein containing: связывающий домен, связывающийся с фиксирующей молекулой; иa binding domain that binds to a fixing molecule; and трансмембранный домен,transmembrane domain при этом белок-метка облегчает очистку вирусного вектора из клеточного супернатанта посредством связывания белка-метки с фиксирующей молекулой.wherein the tag protein facilitates purification of the viral vector from the cell supernatant by binding the tag protein to the fixation molecule. 10. Вирусный вектор по п.9, где связывающий домен белка-метки содержит один или несколько стрептавидин-связывающих эпитопов.10. The viral vector according to claim 9, where the binding domain of the protein tag contains one or more streptavidin-binding epitopes. 11. Вирусный вектор по п.10, где стрептавидин-связывающий эпитоп является миметиком биотина.11. The viral vector of claim 10, where the streptavidin-binding epitope is a biotin mimetic. 12. Вирусный вектор по п.11, где миметик биотина связывается со стрептавидином с более низкой аффинностью, чем биотин, таким образом, что биотин можно использовать для элюции стрептавидин-фиксированных ретровирусных векторов, продуцируемых упаковывающей клеткой.12. The viral vector of claim 11, wherein the biotin mimetic binds to streptavidin with a lower affinity than biotin, so that biotin can be used to elute streptavidin-fixed retroviral vectors produced by the packaging cell. 13. Вирусный вектор по п.12, где миметик биотина выбран из следующей группы: StreptagII (SEQ ID NO: 36), Flankedccstretag (SEQ ID NO: 37) и ccstreptag (SEQ ID NO: 38).13. The viral vector of claim 12, wherein the biotin mimetic is selected from the following group: StreptagII (SEQ ID NO: 36), Flankedccstretag (SEQ ID NO: 37), and ccstreptag (SEQ ID NO: 38). 14. Вирусный вектор по п.1, содержащий последовательность нуклеиновой кислоты, кодирующую T-клеточный рецептор или химерный антигенный рецептор.14. The viral vector of claim 1, comprising a nucleic acid sequence encoding a T cell receptor or a chimeric antigenic receptor. 15. Вирусный вектор по п.1, являющийся вирусоподобной частицей (VLP)15. The viral vector according to claim 1, which is a virus-like particle (VLP) 16. Клетка-хозяин, экспрессирующая на клеточной поверхности16. A host cell expressing on the cell surface (i) митогенный, активирующий T-клетки трансмембранный белок, содержащий митогенный домен и трансмембранный домен; и/или(i) a mitogenic T cell activating transmembrane protein comprising a mitogenic domain and a transmembrane domain; and / or (ii) активирующий T-клетки трансмембранный белок на основе цитокинов, содержащий цитокиновый домен и трансмембранный домен(ii) a T cell activating cytokine-based transmembrane protein comprising a cytokine domain and a transmembrane domain таким образом, что ретровирусный или лентивирусный вектор, продуцируемый клеткой-хозяином, определен в любом из пп.1-8.such that the retroviral or lentiviral vector produced by the host cell is defined in any one of claims 1 to 8. 17. Клетка-хозяин по п.16, также экспрессирующий на клеточной поверхности:17. The host cell according to clause 16, also expressing on the cell surface: (iii) белок-метку, содержащий:(iii) a tag protein containing: связывающий домен, связывающийся с фиксирующей молекулой; иa binding domain that binds to a fixing molecule; and трансмембранный домен,transmembrane domain при этом белок-метка облегчает очистку вирусного вектора из клеточного супернатанта посредством связывания белка-метки с фиксирующей молекулой,wherein the tag protein facilitates purification of the viral vector from the cell supernatant by binding the tag protein to a fixing molecule, таким образом, что ретровирусный или лентивирусный вектор, продуцируемый упаковывающей клеткой, является таким, как определено в любом из пп.9-14.such that the retroviral or lentiviral vector produced by the packaging cell is as defined in any one of claims 9-14. 18. Упаковывающая клетка, являющаяся клеткой-хозяином по п.16 или 17, также содержащая один или несколько следующих генов: gag, pol, env и/или rev.18. The packaging cell, which is the host cell according to clause 16 or 17, also containing one or more of the following genes: gag, pol, env and / or rev. 19. Продуцирующая клетка, являющаяся клеткой-хозяином по п.16 или 17, содержащей гены gag, pol, env и, необязательно, rev, а также содержащая ретровирусный или лентивирусный геном.19. The producing cell, which is the host cell according to clause 16 or 17, containing the genes gag, pol, env and, optionally, rev, and also containing the retroviral or lentiviral genome. 20. Способ получения клетки-хозяина по п.16 или 17, включающий стадию трансдукции или трансфекции клетки с использованием нуклеиновой кислоты, кодирующей митогенный, активирующий T-клетки трансмембранный белок и/или активирующий T-клетки трансмембранный белок на основе цитокинов.20. A method for producing a host cell according to claim 16 or 17, comprising the step of transducing or transfecting the cell using a nucleic acid encoding a mitogenic, T-cell activating transmembrane protein and / or T-cell activating cytokine-based transmembrane protein. 21. Способ получения упаковывающей клетки по п.18, включающий стадию трансдукции или трансфекции клетки с использованием нуклеиновой кислоты, кодирующей митогенный, активирующий T-клетки трансмембранный белок и/или активирующий T-клетки трансмембранный белок на основе цитокинов.21. The method of producing a packaging cell according to claim 18, comprising the step of transducing or transfecting the cell using a nucleic acid encoding a mitogenic, T-cell activating transmembrane protein and / or T-cell activating cytokine-based transmembrane protein. 22. Способ получения продуцирующей клетки по п.19, включающий стадию трансдукции или трансфекции клетки с использованием нуклеиновой кислоты, кодирующей митогенный, активирующий T-клетки трансмембранный белок и/или активирующий T-клетки трансмембранный белок на основе цитокинов.22. The method of producing a producing cell according to claim 19, comprising the step of transducing or transfecting the cell using a nucleic acid encoding a mitogenic, T-cell-activating transmembrane protein and / or T-cell-activating cytokine-based transmembrane protein. 23. Способ получения вирусного вектора по любому из пп.1-15, включающий стадию экспрессии ретровирусного или лентивирусного генома в клетке по любому из пп.17-19.23. The method of obtaining the viral vector according to any one of claims 1 to 15, comprising the step of expressing the retroviral or lentiviral genome in the cell according to any one of claims 17-19. 24. Способ получения активированной трансгенной T-клетки или естественного киллера (NK), включающий стадию трансдукции T- или NK-клетки с использованием вирусного вектора по любому из пп.1-15, таким образом, что T-клетку или NK-клетку активируют одним или несколькими митогенными, активирующими T-клетки трансмембранными белками и/или одним или несколькими активирующими T-клетки трансмембранными белками на основе цитокинов.24. A method of producing an activated transgenic T cell or natural killer (NK), comprising the step of transducing a T or NK cell using the viral vector according to any one of claims 1 to 15, so that the T cell or NK cell is activated one or more mitogenic T cell activating transmembrane proteins and / or one or more T cell activating cytokine-based transmembrane proteins. 25. Набор для получения ретровирусного или лентивирусного вектора по любому из пп.1-15, содержащий:25. A kit for producing a retroviral or lentiviral vector according to any one of claims 1 to 15, comprising: (i) клетку-хозяина по п.16 или 17;(i) the host cell according to claim 16 or 17; (ii) нуклеиновые кислоты, содержащие gag, pol, env и, необязательно, rev; и(ii) nucleic acids containing gag, pol, env and, optionally, rev; and (iii) ретровирусный геном.(iii) the retroviral genome. 26. Набор для получения ретровирусного или лентивирусного вектора по любому из пп.1-15, содержащий:26. A kit for producing a retroviral or lentiviral vector according to any one of claims 1 to 15, comprising: (i) упаковывающую клетку по п.18; и(i) the packaging cage according to claim 18; and (ii) ретровирусный или лентивирусный геном.(ii) a retroviral or lentiviral genome. 27. Набор для получения упаковывающей клетки по п.18, содержащий:27. A kit for producing a packaging cell according to claim 18, comprising: (i) одну или несколько нуклеиновых кислот, кодирующих митогенный, активирующий T-клетки трансмембранный белок и/или активирующий T-клетки трансмембранный белок на основе цитокинов; и(i) one or more nucleic acids encoding a mitogenic, T-cell activating transmembrane protein and / or T-cell activating cytokine-based transmembrane protein; and (ii) нуклеиновые кислоты, содержащие ретровирусные гены gag, pol, env и, необязательно, rev.(ii) nucleic acids containing retroviral genes gag, pol, env and, optionally, rev. 28. Набор для получения продуцирующей клетки по п.19, содержащий:28. A kit for producing a producing cell according to claim 19, containing: (i) одну или несколько нуклеиновых кислот, кодирующих митогенный, активирующий T-клетки трансмембранный белок и/или активирующий T-клетки трансмембранный белок на основе цитокинов;(i) one or more nucleic acids encoding a mitogenic, T-cell activating transmembrane protein and / or T-cell activating cytokine-based transmembrane protein; (ii) нуклеиновые кислоты, содержащие ретровирусные гены gag, pol, и env и, необязательно, rev; и(ii) nucleic acids containing the retroviral genes gag, pol, and env and, optionally, rev; and (iii) ретровирусный или лентивирусный геном.(iii) the retroviral or lentiviral genome.
RU2017133854A 2015-03-02 2016-03-01 VECTOR RU2017133854A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201503500A GB201503500D0 (en) 2015-03-02 2015-03-02 Cell
GB1503500.9 2015-03-02
PCT/GB2016/050537 WO2016139463A1 (en) 2015-03-02 2016-03-01 Retroviral and lentiviral vectors

Publications (2)

Publication Number Publication Date
RU2017133854A true RU2017133854A (en) 2019-04-02
RU2017133854A3 RU2017133854A3 (en) 2019-07-30

Family

ID=52876362

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017133854A RU2017133854A (en) 2015-03-02 2016-03-01 VECTOR

Country Status (16)

Country Link
US (2) US10954530B2 (en)
EP (2) EP3265570B2 (en)
JP (3) JP6695347B2 (en)
KR (1) KR20180002602A (en)
CN (1) CN107406860A (en)
AU (1) AU2016227474A1 (en)
BR (1) BR112017018251A2 (en)
CA (1) CA2977472A1 (en)
CL (1) CL2017002199A1 (en)
ES (1) ES2877398T5 (en)
GB (1) GB201503500D0 (en)
IL (1) IL253820B (en)
MX (1) MX2017010553A (en)
RU (1) RU2017133854A (en)
SG (1) SG11201706721PA (en)
WO (1) WO2016139463A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3831398A1 (en) 2013-10-25 2021-06-09 PsiOxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
KR101697473B1 (en) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 Method for Preparation of Natural Killer Cells Using T Cells
KR20180118249A (en) 2015-04-30 2018-10-30 싸이오서스 테라퓨틱스 엘티디. Oncolytic adenovirus encoding a b7 protein
US10046317B2 (en) * 2015-08-11 2018-08-14 Chevron U.S.A. Inc. Middle distillate hydrocracking catalyst containing zeolite beta with low OD acidity and large domain size
CN108474002B (en) 2015-10-22 2023-05-23 朱诺治疗学有限公司 Methods, reagent kits, reagents and equipment for transduction
AU2016369485B2 (en) 2015-12-17 2024-02-01 Akamis Bio Limited Group B adenovirus encoding an anti-TCR-complex antibody or fragment
BR112018069075A2 (en) * 2016-03-19 2019-01-29 F1 Oncology, Inc. methods and compositions for transducing lymphocytes and regulated expansion thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
GB201614093D0 (en) * 2016-08-17 2016-09-28 Autolus Ltd Vector
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3033267A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
WO2018106732A1 (en) * 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
WO2018120842A1 (en) * 2016-12-30 2018-07-05 上海欣百诺生物科技有限公司 Bifunctional molecule and use thereof
US11535666B2 (en) * 2016-12-30 2022-12-27 Cytocares (Shanghai) Inc. Trifunctional molecule and application thereof
KR20250160517A (en) * 2017-03-03 2025-11-13 엑수마 바이오테크, 코포레이션 Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
AU2018271755B2 (en) 2017-05-26 2021-12-23 Green Cross Lab Cell Corporation Method for culturing natural killer cell, using transformed T cell
CN111479921B (en) * 2017-09-18 2024-08-02 埃克苏马生物技术公司 Methods and compositions for genetically modifying and amplifying lymphocytes and modulating their activity
US11957715B2 (en) * 2017-12-20 2024-04-16 Miltenyi Biotec B.V. & Co. KG Method for NK cell transduction
JP7721436B2 (en) 2018-04-12 2025-08-12 ウモジャ バイオファーマ インコーポレイテッド Viral vectors and packaging cell lines
AU2019318021B2 (en) * 2018-08-10 2025-01-30 Kyoto University Method for producing CD3-positive cell
CA3111084A1 (en) * 2018-09-02 2020-03-05 Exuma Biotech, Corp Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
PH12021550950A1 (en) 2018-11-14 2022-05-02 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t cells
WO2020106992A1 (en) 2018-11-21 2020-05-28 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
CN109722420A (en) * 2019-03-15 2019-05-07 江苏艾洛特医药研究院有限公司 A kind of preparation and its application improveing Chimeric antigen receptor T cell
KR20230031981A (en) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 Methods and compositions for preventing type 1 diabetes
US20240122978A1 (en) * 2019-10-16 2024-04-18 Umoja Biopharma, Inc. Retroviral vector for univeral receptor therapy
CA3165713A1 (en) 2020-01-30 2021-08-05 Andrew Scharenberg Bispecific transduction enhancer
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for preventing type 1 diabetes
MX2023005876A (en) 2020-11-20 2023-07-20 Umoja Biopharma Inc Vector system for delivery of multiple polynucleotides and uses thereof.
AU2022212952A1 (en) 2021-01-27 2023-08-10 Umoja Biopharma, Inc. Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
CN112941039A (en) * 2021-02-01 2021-06-11 南京大学 Novel vesicular oncolytic virus and application thereof in preparation of antitumor drugs
WO2023143209A1 (en) * 2022-01-25 2023-08-03 广东东阳光药业股份有限公司 Viral vector and application thereof
CN119365208A (en) 2022-04-13 2025-01-24 巴塞罗那自治大学 Treating neuromuscular diseases by gene therapy expressing KLOTHO protein
EP4525899A1 (en) 2022-05-17 2025-03-26 Umoja Biopharma, Inc. Manufacturing viral particles
IL320319A (en) 2022-11-04 2025-06-01 Umoja Biopharma Inc Lentiviral particles displaying fusion molecules and uses thereof
CN120475987A (en) 2022-11-04 2025-08-12 优莫佳生物制药股份有限公司 Polynucleotide constructs and related viral vectors and methods
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN120769904A (en) * 2023-02-27 2025-10-10 上海君赛生物科技有限公司 Tumor-infiltrating lymphocytes expressing membrane-bound cytokines
WO2024223847A1 (en) * 2023-04-27 2024-10-31 Miltenyi Biotec B.V. & Co. KG Pseudotyped retroviral vector particle with anti-cd3 display
WO2024238153A1 (en) 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
CN116496417B (en) * 2023-06-27 2023-10-10 北京市肿瘤防治研究所 Fusion protein and T cells containing membrane-type IL7
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer
WO2025072257A1 (en) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Compositions for treating cancer
US12269882B1 (en) 2023-09-25 2025-04-08 Kelonia Therapeutics, Inc. Antigen binding polypeptides
WO2025090978A1 (en) 2023-10-26 2025-05-01 Cargo Therapeutics, Inc. Modified immune effector cells
WO2025149068A1 (en) * 2024-01-10 2025-07-17 深圳市济因生物科技有限公司 Viral particle, and preparation method therefor and use thereof
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7097494A (en) * 1993-06-01 1994-12-20 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
WO1997005266A1 (en) * 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
US7407777B2 (en) 2003-03-07 2008-08-05 University Of Utah Research Foundation IL-2 transmembrane construct
WO2006007539A1 (en) 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
WO2007095201A2 (en) * 2006-02-15 2007-08-23 The Regents Of The University Of California Pseudotyped retroviral vectors and methods of use thereof
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
GB0920775D0 (en) * 2009-11-26 2010-01-13 King S College Cells
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
GB201614093D0 (en) 2016-08-17 2016-09-28 Autolus Ltd Vector
GB201910651D0 (en) 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle

Also Published As

Publication number Publication date
EP3265570B1 (en) 2021-05-05
ES2877398T3 (en) 2021-11-16
GB201503500D0 (en) 2015-04-15
US10954530B2 (en) 2021-03-23
AU2016227474A1 (en) 2017-08-31
ES2877398T5 (en) 2025-12-02
CA2977472A1 (en) 2016-09-09
CN107406860A (en) 2017-11-28
JP6695347B2 (en) 2020-05-20
IL253820B (en) 2021-03-25
KR20180002602A (en) 2018-01-08
US20180066280A1 (en) 2018-03-08
JP2020092722A (en) 2020-06-18
WO2016139463A1 (en) 2016-09-09
US11814641B2 (en) 2023-11-14
RU2017133854A3 (en) 2019-07-30
SG11201706721PA (en) 2017-09-28
JP2023060000A (en) 2023-04-27
JP2018506983A (en) 2018-03-15
EP3904523A1 (en) 2021-11-03
EP3265570A1 (en) 2018-01-10
IL253820A0 (en) 2017-09-28
US20210348191A1 (en) 2021-11-11
MX2017010553A (en) 2018-03-15
EP3265570B2 (en) 2025-07-23
CL2017002199A1 (en) 2018-03-16
BR112017018251A2 (en) 2018-04-10

Similar Documents

Publication Publication Date Title
RU2017133854A (en) VECTOR
JP2018506983A5 (en)
Yang et al. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
Stano et al. Dense array of spikes on HIV-1 virion particles
Kolchinsky et al. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops
Grundner et al. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins
Egelhofer et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides
Henzy et al. Pushing the endogenous envelope
Yang et al. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution
JP2019150066A5 (en)
Yang et al. Role of the gp120 inner domain β-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits
Lévy et al. Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells
Maerz et al. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association
JP2015513920A5 (en)
US20050048478A9 (en) Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection
Hammonds et al. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization
Kamdem Toukam et al. Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus
Hogan et al. Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization
Tailor et al. Variable regions A and B in the envelope glycoproteins of feline leukemia virus subgroup B and amphotropic murine leukemia virus interact with discrete receptor domains
de Taeye et al. Stabilization of the V2 loop improves the presentation of V2 loop–associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers
ES2683820T3 (en) Use of non-subtype B GAG proteins for lentiviral encapsidation
Vahlenkamp et al. A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism
Bruun et al. Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins
Liu et al. Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16
CN108484778B (en) Chimeric antigen receptor construct of humanized GHR106 monoclonal antibody, nucleic acid molecule and application

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20211224